TY - JOUR
T1 - How to Sequence Therapies in Mycosis Fungoides
AU - Brumfiel, Caitlin M.
AU - Patel, Meera H.
AU - Puri, Pranav
AU - Besch-Stokes, Jake
AU - Lester, Scott
AU - Rule, William G.
AU - Khera, Nandita
AU - Sluzevich, Jason C.
AU - DiCaudo, David J.
AU - Comfere, Nneka
AU - Bennani, N. Nora
AU - Rosenthal, Allison C.
AU - Pittelkow, Mark R.
AU - Mangold, Aaron R.
N1 - Publisher Copyright:
© 2021, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
PY - 2021/11
Y1 - 2021/11
N2 - Choice of therapy in mycosis fungoides is based on both patient- and lymphoma-specific factors, such as disease characteristics, comorbidities, symptoms and effect on quality of life, potential associated toxicities of therapy, response and tolerance to prior lines of therapy, and convenience and practicality. Generally, we sequence therapies from least toxic, targeted, nonimmunosuppressive to more toxic, immunosuppressive and from single agent to multiple agents, as necessary. If more toxic, immunosuppressive agents are required to alleviate disease burden or symptoms, we generally use them just long enough to control the disease, then transition to a maintenance regimen with less toxic, less immunosuppressive agents.
AB - Choice of therapy in mycosis fungoides is based on both patient- and lymphoma-specific factors, such as disease characteristics, comorbidities, symptoms and effect on quality of life, potential associated toxicities of therapy, response and tolerance to prior lines of therapy, and convenience and practicality. Generally, we sequence therapies from least toxic, targeted, nonimmunosuppressive to more toxic, immunosuppressive and from single agent to multiple agents, as necessary. If more toxic, immunosuppressive agents are required to alleviate disease burden or symptoms, we generally use them just long enough to control the disease, then transition to a maintenance regimen with less toxic, less immunosuppressive agents.
KW - CTCL
KW - Cutaneous T cell lymphoma
KW - Cutaneous oncology
KW - Lymphoma
KW - Mycosis fungoides
UR - http://www.scopus.com/inward/record.url?scp=85115833656&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85115833656&partnerID=8YFLogxK
U2 - 10.1007/s11864-021-00899-0
DO - 10.1007/s11864-021-00899-0
M3 - Review article
C2 - 34570278
AN - SCOPUS:85115833656
SN - 1527-2729
VL - 22
JO - Current treatment options in oncology
JF - Current treatment options in oncology
IS - 11
M1 - 101
ER -